NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.640
-0.080 (-2.94%)
At close: Aug 5, 2025, 4:00 PM
2.710
+0.070 (2.65%)
After-hours: Aug 5, 2025, 7:30 PM EDT

Company Description

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.

Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression.

The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital.

NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals logo
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees2
CEOJonathan Javitt

Contact Details

Address:
1201 Orange Street, Suite 600
Wilmington, Delaware 19801
United States
Phone484 254 6134
Websitenrxpharma.com

Stock Details

Ticker SymbolNRXP
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001719406
CUSIP Number629444209
ISIN NumberUS6294442099
Employer ID82-2844431
SIC Code2834

Key Executives

NamePosition
Matthew Patrick DuffyChief Business Officer and Co-Chief Executive Officer of Hope Therapeutics
Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chief Scientist Officer, Chairman and Interim Chief Executive Officer
Michael S. AbramsChief Financial Officer
Dr. Riccardo Panicucci Ph.D.Chief Manufacturing and Technology Officer
Suzanne MessereInvestor Relations
Dr. Philip T. Lavin Ph.D.Chief Methodologist

Latest SEC Filings

DateTypeTitle
Jun 24, 2025RWFiling
Jun 20, 2025S-3Registration statement under Securities Act of 1933
Jun 9, 20258-KCurrent Report
May 21, 20258-KCurrent Report
May 15, 2025SCHEDULE 13GFiling
May 15, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
Apr 30, 202510-K/A[Amend] Annual report
Apr 17, 20258-KCurrent Report
Apr 17, 2025424B3Prospectus